MONTREAL, QUEBEC--(Marketwired - Sept. 28, 2015) - Knight Therapeutics Inc. (TSX:GUD), through one of its wholly-owned subsidiaries, ("Knight") announced today that it has entered into an exclusive distribution agreement with Profounda Inc. ("Profounda") to commercialize Impavido®(miltefosine), an oral treatment for visceral, mucosal and cutaneous leishmaniasis, in the United States. Knight previously licensed the ex-U.S. global rights to Impavido® to Paladin Labs Inc. until February, 2024.
Under the terms of the agreement, Profounda will be responsible for leading all commercial activities related to Impavido® in the United States in exchange for a share of Impavido®'s U.S. net sales. Knight is responsible for product supply and regulatory management.
"This agreement will ensure ease of availability in the U.S. for Impavido®, the only FDA approved, oral treatment for leishmaniasis. We are confident we have found a GUD partner in Profounda in that they share our motivation to touch the lives of patients in need," said Jonathan Ross Goodman, Director of Knight.
"We are pleased to be working with Knight on launching Impavido® in the U.S.," said Todd MacLaughlan, President and CEO of Profounda. "We appreciate the trust that Jonathan Goodman and his team have placed in us to make this important product available to patients in the United States."
Impavido® (Miltefosine) is an FDA-approved, oral treatment for visceral, mucosal and cutaneous leishmaniasis in patients 12 years of age and older. In the United States, leishmaniasis may be seen in returning travelers following exposure in endemic regions, and in American soldiers serving in regions such as Asia and the Middle East. Impavido® is approved for marketing in 14 countries worldwide.
About Knight Therapeutics Inc.:
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutic Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com.
About Profounda, Inc.
Profounda is a product-oriented, privately backed pharmaceutical company that aims to license or develop high quality specialty niche pharmaceutical products in both the branded and generic pharmaceutical markets. Profounda's objective is to focus on bringing high quality innovative options to patients being treated for various conditions in order to improve the lives of those that take our medication. Profounda's first commercial OTC products, Rhinase® Nasal Gel and Rhinase® Nasal Mist, will help patients with nasal dryness associated with allergies. Profounda is also developing a potential first to file generic product competing in a $100+ million brand market. For more information, visit Profounda's website at www.profounda.com.
This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2014. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.